Ingredient Dictionary/gluconolactone/GLUCONOLACTONE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
Synthetic

GLUCONOLACTONE

ChelatingSkin Conditioning
[EU CosIng Official Definition] D-Glucono-1,5-lactone
Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR

What is GLUCONOLACTONE (CAS 90-80-2) in cosmetics and what are its global regulatory limits?

GLUCONOLACTONE (CAS No. 90-80-2) is a verified cosmetic ingredient primarily functioning as Chelating, Skin Conditioning in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 1–10% within an optimal stability window of pH 3.6–4.8.

7-Track Official Regulatory Label Names Matrix

Primary Statutory Gazette Only · Zero Machine Translation
7-Track Official Statutory Label Names for GLUCONOLACTONE
Jurisdiction TrackOfficial Statutory Label NameOne-Click Copy
1. Korea (MFDS Standard Name)GLUCONOLACTONE (KR MFDS Registered)
2. Korea Former Nomenclature History——
3. European Union (EU CosIng Glossary)GLUCONOLACTONE
4. United States (US PCPC / MoCRA INCI)GLUCONOLACTONE
5. US FDA OTC Monograph Active Name— (Cosmetic Inactive / Non-OTC)—
6. China (NMPA IECIC Standard Name)葡糖酸内酯
7. Japan (JCIA Standard / MHLW Quasi-Drug)GLUCONOLACTONE (Standard INCI Reference)

Layer 1 — Statutory Regulatory Limits Across 6 Regions

Layer 1 Statutory Regulatory Limits Across 6 Regions for GLUCONOLACTONE
RegionStatusMax LimitConditions & Statutory Source
Korea (MFDS)UnregulatedGMPListed in official cosmetic inventory
Europe (EU)UnregulatedGMPListed in official cosmetic inventory
United States (FDA)UnregulatedGMPListed in official cosmetic inventory
China (NMPA)Listed / AllowedGMPIECIC Entry #5123
Japan (MHLW)UnregulatedGMPListed in official cosmetic inventory
ASEAN (ACD)UnregulatedGMPListed in official cosmetic inventory

Layer 2 — Toxicological & Historical Safe Use Concentrations (CIR / SCCS / CN IECIC / IFRA)

“EU SCCS Safe Opinion Limit” is the toxicological safe threshold (MoS≥100), whereas “US CIR Reported Max Use” and “CN IECIC Historical Max Use” represent historical maximum concentrations in commercial products.

Layer 2 Toxicological & Historical Safe Use Concentrations for GLUCONOLACTONE
Assessment BasisApplication ScopeConcentration RangeVerdict & Dossier Reference
CN IECIC Historical Max Useleave_on≤ 10%Safe (MoS≥100)NMPA IECIC (2025) Entry 05082 (2025)
CN IECIC Historical Max Userinse_off≤ 6%Safe (MoS≥100)NMPA IECIC (2025) Entry 05082 (2025)
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Aqueous Serum / Ampoulen=42
Min 1% · Q1 2% · Median 4% · Q3 6% · Max 10%
Aqueous Serum / Ampoule — Non-irritating Polyhydroxy Acid (PHA) gentle exfoliant, humectant & antioxidant chelator
Verified Source: Jungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies (cir_safety) · Jungbunzlauer · NeoStrata · K-Beauty
Typical Median: 4%

Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility

Layer 3 Formulation Concentration Quartiles by Product Category for GLUCONOLACTONE
Formulation GroupMin – Q1 – Median – Q3 – Max (%)Role & MechanismSource ID
Group A — Aqueous Toner / Serum / Ampoule1% · 2% · 4% · 6% · 10%Non-irritating Polyhydroxy Acid (PHA) gentle exfoliant, humectant & antioxidant chelatorJungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies
Cutaneous Permeation Science (500 Dalton Rule)MW: 178.14 Da · LogP: -1.98

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (178.14 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Freely soluble in water (~59 g/100mL)
Optimal Formulation pH Stability Window (0–14)pH 3.6 – 4.8
0245.5791114

Outside pH 3.6–4.8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 70°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 70°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ LACTOBIONIC ACID+ SALICYLIC ACID+ ARGININE+ SODIUM CITRATE+ POLYACRYLATE CROSS…✕ CRITICAL FORMULATION…GLUCONOLACTONE
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

Nominative Trade Name References (Trademark Act Art. 90(1)(2))
Jungbunzlauer Gluconolactone USP/FCC

Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.

Academic & Toxicological Synthesis

Tier 1 Synthesis

Synthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: GLUCONOLACTONE | CAS No.: 90-80-2 | EC No.: 202-016-5 - Origin: SYNTHETIC | Functions: , - Physicochemical Profile: Formula C6H10O6 | MW 178.14 g/mol | LogP -1.98 | Ionic Nature: anionic | PubChem CID 7027 - Official Regional Label Names: US [GLUCONOLACTONE] · EU [GLUCONOLACTONE] · CN [葡糖酸内酯] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Cyclic polyhydroxy acid (PHA) lactone bearing multiple hydroxyl groups upon hydrolysis to gluconic acid. Provides gentle stratum corneum exfoliation without sensory stinging due to larger molecular size, coupled with humectancy, metal-chelating antioxidant activity, and barrier strengthening. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 5123 (葡糖酸内酯)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 10.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 6.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [aqueous_serum] Typical range: 1.0 ~ 10.0% (Median 4.0%, Ref: Jungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies) — Non-irritating Polyhydroxy Acid (PHA) gentle exfoliant, humectant & antioxidant chelator ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase (Account for gradual hydrolysis into Gluconic Acid — buffer with Sodium Citrate / Arginine / NaOH) - Optimal pH Range: pH 3.6 ~ 4.8 | Max Process Temp: Max 70°C | Electrolyte Tolerance: NONE - Incompatibility / Caution: CRITICAL FORMULATION HAZARD (pH Drift): Slowly hydrolyzes in water from a neutral lactone ring into free Gluconic Acid (pKa 3.86) over days/weeks, causing severe pH drop (down to pH < 3.0) and emulsion/viscosity breakdown! Pre-equilibrate in warm water and buffer with Sodium Citrate / Arginine + use SEPIMAX ZEN - Synergy Pairings: LACTOBIONIC ACID, SALICYLIC ACID, ARGININE, SODIUM CITRATE, POLYACRYLATE CROSSPOLYMER-6 | Reference Trade Names: Jungbunzlauer Gluconolactone USP/FCC ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 42249663 (2026, Int J Toxicol): Safety Assessment of Glycolactones as Used in Cosmetics - PMID 41668671 (2026, Int J Cosmet Sci): The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolacton - PMID 41215631 (2026, Adv Healthc Mater): Versatile Hyaluronic Acid Hydrogels via pH-Induced Gelation for Multifaceted Cutaneous Wound Healing

Linked Peer-Reviewed Literature (NIH PubMed) (12)

Safety Assessment of Glycolactones as Used in Cosmetics [PMID: 42249663 · 2026]
Ferguson P, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Peterson LA, Rettie AE, Ross D, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B · Int J Toxicol (2026)

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 5 glycolactone ingredients. Glucoheptonolactone and Gluconolactone are reported to function in cosmetics as skin-conditioning agents-miscellaneous, and Gluconolactone is also reported to function as a chelating agent. No functions are reported for the other 3 ingredients. The Panel considered the available data and concluded that Gluconolactone is safe in cosmetics in the present practices of use and concentration described in this safety assessment; however, the Panel concluded the available data are insufficient to make a determination that Galactonolactone, Glucarolactone, Glucoheptonolactone, and Ribonolactone are safe under the intended conditions of use in cosmetic formulations.

The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies [PMID: 41668671 · 2026]
Zhu M, He X, Zhu Z, Lynch S, Wang H, Zhou X, Tu Y, Steel A, Hsu KC, Niu Y, Cho A, Hashimoto M, Yan X, Su M, Wang W · Int J Cosmet Sci (2026)

This study aimed to explore the anti-skin aging efficacy of a novel serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract through one ex-vivo study and two clinical studies. In ex-vivo study, skin samples were exposed to the serum (Formula 1) and its active ingredient combinations (Formula 2). Biomarkers including matrix metalloproteinase-1, elastic fibres and collagen types I, III, IV and XVII content were analyzed to evaluate the efficacy. In clinical study 1 (n&#x2009;=&#x2009;50), the Formula 1's efficacy in reducing static wrinkles and improving skin quality was examined, while study 2 (n&#x2009;=&#x2009;42) focused on its efficacy against dynamic wrinkles. Formula 1 significantly increased levels of anti-aging biomarkers including elastic fibres, collagen fibres, etc. Meanwhile, Formula 1 significantly improved static wrinkle appearance within the first week, with mean clinical scoring from 35% to 69% for various types of wrinkles after 12&#x2009;weeks of use (all&#xa0;p&#x2009;&lt;&#x2009;0.001). The clinical scoring for dynamic wrinkles improved by 10%-13% (all p&#x2009;&lt;&#x2009;0.001). Additionally, significant improvements were observed in skin quality, indicated by clinical scoring changes of smoothness (30%), radiance (27%), skin pore (43%), elasticity (33%) and firmness (36%) (all p&#x2009;&lt;&#x2009;0.001). The serum demonstrates significant anti-aging effects, effectively improving static and dynamic wrinkles and skin quality. cette &#xe9;tude visait &#xe0; &#xe9;tudier l'efficacit&#xe9; sur la peau d'un nouveau s&#xe9;rum anti&#x2010;&#xe2;ge contenant de l'hexapeptide ac&#xe9;tyl&#x2010;8, du dipeptide diaminobutyroyl benzylamide diac&#xe9;tate, de la gluconolactone, de la niacinamide et de l'extrait de laminaire dans le cadre d'une &#xe9;tude ex&#x2010;vivo ainsi que de deux &#xe9;tudes cliniques. M&#xc9;THODES: dans une &#xe9;tude ex&#x2010;vivo, des &#xe9;chantillons de peau ont &#xe9;t&#xe9; expos&#xe9;s au s&#xe9;rum (Formule 1) et &#xe0; ses associations de principes actifs (Formule 2). Des analyses des biomarqueurs, notamment de la m&#xe9;talloprot&#xe9;inase&#x2010;1 matricielle, des fibres &#xe9;lastiques et des collag&#xe8;nes de type I, III, IV et XVII, ont permis d'&#xe9;valuer l'efficacit&#xe9;. Dans l'&#xe9;tude clinique 1 (n&#x2009;=&#x2009;50), l'efficacit&#xe9; de la Formule 1 dans la r&#xe9;duction des rides statiques et l'am&#xe9;lioration de la qualit&#xe9; de la peau a &#xe9;t&#xe9; examin&#xe9;e, alors que l'&#xe9;tude 2 (n&#x2009;=&#x2009;42) portait sur son efficacit&#xe9; contre les rides dynamiques. R&#xc9;SULTATS: la Formule 1 a significativement augment&#xe9; les taux de biomarqueurs anti&#x2010;&#xe2;ges, y compris les fibres &#xe9;lastiques, les fibres de collag&#xe8;ne, etc. Qui plus est, la Formule 1 a significativement am&#xe9;lior&#xe9; l'aspect des rides statiques au cours de la premi&#xe8;re semaine, le score clinique moyen &#xe9;tant de 35% &#xe0; 69% pour diff&#xe9;rents types de rides apr&#xe8;s 12 semaines d'utilisation (p&#x2009;&lt;&#x2009;0,001 pour tous). Le score clinique pour les rides dynamiques s'est am&#xe9;lior&#xe9; de 10 &#xe0; 13% (p &lt;&#x2009;0,001 pour toutes). En outre, des am&#xe9;liorations significatives ont &#xe9;t&#xe9; observ&#xe9;es au niveau de la qualit&#xe9; de la peau, indiqu&#xe9;es par des changements de notation clinique de la douceur (30%), de l'&#xe9;clat (27%), des pores cutan&#xe9;s (43%), de l'&#xe9;lasticit&#xe9; (33%) et de la fermet&#xe9; (36%) (p&#x2009;&lt;&#x2009;0,001 pour toutes). le s&#xe9;rum a d&#xe9;montr&#xe9; des effets anti&#x2010;&#xe2;ges significatifs en am&#xe9;liorant efficacement les rides statiques et dynamiques ainsi que la qualit&#xe9; de la peau.

Versatile Hyaluronic Acid Hydrogels via pH-Induced Gelation for Multifaceted Cutaneous Wound Healing [PMID: 41215631 · 2026]
Yang X, Wu K, Liu Y, Liu Y, Fu Y, Lin W, Mao Z, Wang X, Guo H · Adv Healthc Mater (2026)

Hyaluronic acid (HA) hydrogels have attracted growing interest for&#xa0;skin regeneration. However, conventional fabrication approaches for HA hydrogels often require complex chemical modifications, leading to prolonged preparation cycles, inconsistent batch reproducibility, and elevated toxicity. Herein, a straightforward strategy is presented for developing pure yet multifunctional HA hydrogels by regulating the pH. Specifically, highly concentrated HA solutions are initially prepared at high pH, followed by gradual neutralization mediated by the hydrolysis of gluconolactone (GdL). This pH-triggered process promotes the reformation of intermolecular hydrogen bonds, thereby culminating in a sol-to-gel transition. Owing to this unique formation mechanism, the HA-GdL (HG) hydrogels exhibit strong adhesiveness, desirable mechanical toughness, and excellent self-healing properties. Moreover, these dynamic interactions provide the HG hydrogels with injectability, moldability, and 3D printability, enabling the incorporation of therapeutic agents under physiologically benign conditions. In murine-infected wound models, silver nanoparticle-laden HG hydrogels not only conform to the irregular shape of the wounds but also exert anti-bacterial, anti-inflammatory, pro-angiogenic, and immunoregulatory effects to expedite wound closure and regeneration. Collectively, this study offers a streamlined yet highly efficient approach for fabricating versatile HA hydrogel dressings, offering significant promise for the comprehensive management of infected wounds.

Simultaneous determination of sodium hyaluronate and gluconolactone in cosmetic products [PMID: 40525233 · 2025]
Shetty S, Mehta R, Choudhury RP · Int J Cosmet Sci (2025)

The increasing prevalence of sodium hyaluronate and gluconolactone in a wide range of cosmetic formulations has created a crucial need for robust and reliable analytical methods to ensure product quality, optimize formulations and meet regulatory standards. Sodium hyaluronate and gluconolactone, two highly sought-after humectants renowned for their remarkable water-binding properties, present significant analytical challenges during quantification. Sodium hyaluronate, a complex polymeric structure, lacks a UV-absorbing chromophore and gluconolactone needs an indirect technique (derivatization/conversion to gluconic acid) to be quantified, which makes these analyses quite challenging in cosmetic products. This study directly addresses this critical gap in cosmetic analysis by developing and validating a novel method for the simultaneous determination of sodium hyaluronate and gluconolactone in cosmetic compositions. This method employs size exclusion liquid chromatography (SEC), a powerful separation technique ideal for analysing polymers and macromolecules, coupled with sensitive UV detection. Using a BioSep SEC S2000 column and an isocratic mobile phase of 0.05&#x2009;M potassium dihydrogen phosphate (pH&#x2009;7.0), we achieved efficient separation and detection at 205&#x2009;nm, enabling the quantification of both compounds despite the absence of strong chromophores. Rigorous method validation confirmed the reliability and robustness of this approach. The method demonstrated excellent linearity (r 2 &#x2009;&gt;&#x2009;0.999) over a wide concentration range of 25-1000&#x2009;&#x3bc;g/mL for both sodium hyaluronate and gluconolactone, ensuring accurate quantification across diverse formulation concentrations. Additionally, high precision (RSD &#x2264;1.22%), specificity against common cosmetic excipients and satisfactory recovery rates (80%-120%) further validate the method's suitability for routine quality control analysis in the cosmetic industry. This sensitive, accurate and robust SEC-UV method provides a valuable new tool for cosmetic manufacturers to ensure the quality, efficacy and consumer safety of products containing these key ingredients. La pr&#xe9;valence croissante de l&#x2019;hyaluronate de sodium et de la gluconolactone dans un large &#xe9;ventail de formulations cosm&#xe9;tiques a g&#xe9;n&#xe9;r&#xe9; un besoin crucial de m&#xe9;thodes analytiques robustes et fiables pour garantir la qualit&#xe9; du produit, optimiser les formulations et respecter les normes r&#xe9;glementaires. Le hyaluronate de sodium et la gluconolactone, deux humectants tr&#xe8;s recherch&#xe9;s reconnus pour leurs remarquables propri&#xe9;t&#xe9;s de liaison &#xe0; l&#x2019;eau, pr&#xe9;sentent des d&#xe9;fis analytiques significatifs pendant la quantification. Le hyaluronate de sodium, une structure polym&#xe9;rique complexe, ne dispose pas d&#x2019;un chromophore absorbant les UV et la gluconolactone n&#xe9;cessite une technique indirecte (d&#xe9;rivatisation/conversion vers l&#x2019;acide gluconique) pour &#xea;tre quantifi&#xe9;e, ce qui rend ces analyses assez difficiles dans les produits cosm&#xe9;tiques. M&#xc9;THODE: cette &#xe9;tude traite directement cette lacune critique dans l&#x2019;analyse cosm&#xe9;tique en d&#xe9;veloppant et en validant une nouvelle m&#xe9;thode pour la d&#xe9;termination simultan&#xe9;e du hyaluronate de sodium et de la gluconolactone dans les compositions cosm&#xe9;tiques. Cette m&#xe9;thode utilise la chromatographie en phase liquide d&#x2019;exclusion st&#xe9;rique (SEC), une technique de s&#xe9;paration puissante id&#xe9;ale pour analyser les polym&#xe8;res et les macromol&#xe9;cules, associ&#xe9;e &#xe0; une d&#xe9;tection UV sensible. En utilisant une colonne BioSep SEC S2000 et une phase mobile isocratique de dihydrog&#xe9;nophosphate de potassium 0,05 M (pH 7,0), nous avons obtenu une s&#xe9;paration et une d&#xe9;tection efficaces &#xe0; 205 nm, permettant la quantification des deux compos&#x

Comparison of Efficacy and Willingness to a 5% Gluconolactone-Based Topical Serum and Intense Pulsed Light in Mild Erythema of Rosacea: A Paired Control Study [PMID: 40111222 · 2025]
Peng Y, Mao M, Huang Z, Zhao H, Li Y, Jian D · J Cosmet Dermatol (2025)

Mild erythema is a common affliction of rosacea. Many methods including drugs and phototherapy (e.g., Intense Pulse Light, IPL) have been tried to alleviate symptoms. Topical applications for enhancing moisturization have also been thought to be of some benefit. In this study, the improvement of erythema and skin physiology parameters were assessed after a topical serum (5% gluconolactone-based serum) usage or a single IPL treatment, and the differences in improvement between the two groups were compared. The treatment willingness of the subjects was also performed. In this study, 200 subjects with mild erythema were enrolled; 100 of them were treated with topical serum (TS) for 30 consecutive days and the other 100 for a single IPL treatment. Facial images, local skin images, and physiological measurements were collected before and after treatment, to assess erythema (CEA), overall facial condition (VAS), and other skin physiology parameters (e.g., pore, skin tone, and sebum). Based on the questionnaire, the treatment willingness and satisfaction of the subjects were collected. Improvement on erythema, overall facial condition, and skin physiology parameters were observed in two groups. Both subjective assessments and measurements showed greater efficacy in erythema reduction, overall facial condition improvement, and sebum reduction in the IPL group (p&#x2009;&lt;&#x2009;0.05). Pores and skin tone improvement were comparable in TS and IPL groups. Similarly, subjects with certain erythema improvement in both groups were satisfied with their choice of treatment, in which possible side effects, cost, and duration of the treatment somewhat influence their treatment decisions. Topical serum that focuses on redness reduction and moisturization and IPL can improve erythema and skin physiological indicators. IPL is more capable of improving the overall facial appearance. By fully understanding the patient's facial condition and treatment influence, medical practitioners determine the appropriate treatment. ClinicalTrials.gov identifier: ChiCTR2400087665.

Development and Characterization of Biocompatible Chitosan-Aloe Vera Films Functionalized with Gluconolactone and Sorbitol for Advanced Wound Healing Applications [PMID: 39999379 · 2025]
Kaczmarek-Szczepa&#x144;ska B, Glajc P, Chmielniak D, Gwizdalska K, Swiontek Brzezinska M, Dembi&#x144;ska K, Shinde AH, Gierszewska M, &#x141;ukowicz K, Basta-Kaim A, D'Amora U, Zasada L · ACS Appl Mater Interfaces (2025)

Chitosan (CTS) has emerged as a promising biopolymer for wound healing due to its biocompatibility, biodegradability, and intrinsic bioactive properties. This study explores the development and characterization of CTS-based films enhanced with natural bioactive agents, aloe vera (A), gluconolactone (GL), and sorbitol (S), to improve their mechanical, antimicrobial, and regenerative performance for potential use in advanced wound care. A series of CTS-based films were fabricated with varying concentrations of A, GL, and S, and their physicochemical, mechanical, and biological properties were comprehensively evaluated. Fourier transform infrared (FTIR) spectroscopy and atomic force microscopy (AFM) analysis revealed modifications in the film structure attributable to these additives, influencing the surface roughness, hydrophilicity, and thermal stability. Biocidal assays confirmed enhanced antimicrobial activity, particularly in films containing GL and A. Biodegradation studies demonstrated a significant enhancement in microbial decomposition of the films, while cytocompatibility tests confirmed minimal cytotoxic effects and improved cellular response. This research underscores the potential of combining CS with A, GL, and S to engineer multifunctional biomaterials tailored for effectively tackling different phases of the wound healing process, offering a sustainable and biocompatible alternative for clinical applications.

Gluconolactone restores immune regulation and alleviates skin inflammation in lupus-prone mice and in patients with cutaneous lupus [PMID: 39970231 · 2025]
Li W, Kolios AGA, Pan W, Burbano C, Karino K, Vichos T, Humbel M, Kyttaris VC, Tsokos MG, Tsokos GC · Sci Transl Med (2025)

Systemic lupus erythematosus (SLE) is characterized by dysfunctional regulatory T cells (T regs ). We previously showed that protein phosphatase 2A (PP2A) plays a critical role in maintaining the suppressive function of T regs . Here, we analyzed phosphoproteomics and metabolomics data from PP2A-wild type and PP2A-deficient T regs and demonstrated that PP2A regulates T reg function through the pentose phosphate pathway (PPP). Furthermore, we proved that the PPP metabolite gluconolactone (GDL) enhances in vitro induced (i)T reg differentiation and function by promoting forkhead box protein 3 and phosphorylated signal transducer and activator of transcription 5 expression and inhibits T helper 17 (T H 17) differentiation in murine cells. In short-term imiquimod-induced autoimmunity in mice, treatment with GDL alleviates inflammation by inhibiting T H 17 cells. GDL promotes T regs function and alleviates skin lesions in MRL. lpr lupus-prone mice in vivo. It also promotes T regs differentiation and function in ex vivo experiments using cells from patients with SLE. Last, in patients suffering from cutaneous lupus erythematosus, topical application of a GDL-containing cream controlled skin inflammation and improved the clinical and histologic appearance of the skin lesions within 2 weeks. Together, we have identified GDL as a PPP metabolite and showed mechanistically that it restores immune regulation in vitro and in vivo by inducing T reg suppressive function and inhibiting T H 17 cells. GDL should be considered as a treatment approach for inflammatory and autoimmune diseases.

Bioactivation of Konjac Glucomannan Films by Tannic Acid and Gluconolactone Addition [PMID: 39163280 · 2024]
Kaczmarek-Szczepa&#x144;ska B, Zasada L, D'Amora U, Pa&#x142;ubicka A, Michno A, Ronowska A, Wekwejt M · ACS Appl Mater Interfaces (2024)

Wound healing is a dynamic process that requires an optimal extracellular environment, as well as an accurate synchronization between various cell types. Over the past few years, great efforts have been devoted to developing novel approaches for treating and managing burn injuries, sepsis, and chronic or accidental skin injuries. Multifunctional smart-polymer-based dressings represent a promising approach to support natural healing and address several problems plaguing partially healed injuries, including severe inflammation, scarring, and wound infection. Naturally derived compounds offer unique advantages such as minimal toxicity, cost-effectiveness, and outstanding biocompatibility along with potential anti-inflammatory and antimicrobial activity. Herein, the main driving idea of the work was the design and development of konjac glucomannan d-glucono-1,5-lactone (KG) films bioactivated by tannic acid and d-glucono-1,5-lactone (GL) addition. Our analysis, using attenuated total reflectance-Fourier transform infrared, atomic force microscopy, and surface energy measurements demonstrated that tannic acid (TA) clearly interacted with the KG matrix, acting as its cross-linker, whereas GL was embedded within the polymer structure. All developed films maintained a moist environment, which represents a pivotal property for wound dressing. Hemocompatibility experiments showed that all tested films exhibited no hemolytic impact on human erythrocytes. Moreover, the presence of TA and GL enhanced the metabolic and energetic activity in human dermal fibroblasts, as indicated by the MTT assay, showing results exceeding 150%. Finally, all films demonstrated high antibacterial properties as they significantly reduced the multiplication rate of both Staphylococcus aureus and Escherichia coli in bacterial broth and created the inhibition zones for S. aureus in agar plates. These remarkable outcomes make the KG/TA/GL film promising candidates for wound healing applications.

Split-face evaluation: Gluconolactone plus oxybrasion versus gluconolactone plus microneedling. The effects on skin parameters [PMID: 37357656 · 2023]
Jarz&#x105;bek-Perz S, Dziedzic M, Ko&#x142;odziejczak A, Rotsztejn H · Skin Res Technol (2023)

The application of polyhydroxy acids and alpha-hydroxy acids to the skin is often used in cosmetology. To enhance the effect of gluconolactone chemical peeling, a combined method including water-oxygen oxybrasion or microneedle mesotherapy can be used. To evaluate skin parameters such as hydration, sebum, pH and TEWL after application of a 10% gluconolactone chemical peel in combination with oxybrasion and microneedling. Twenty-one Caucasian women participated in the study. A series of three split face treatments was carried out at 1-week intervals. Oxybrasion was performed on the right side of the face and micro-needle mesotherapy on the left side. A 10% gluconolactone solution was applied to the entire face. Before the first and third treatments and 2 weeks after the last treatment, skin parameters were evaluated. Photographic documentation was also made before and after the treatment series. Evaluation of skin parameters using Courage &amp; Khazaka 580 Multi Probe Adapter probes (Courage + Khazaka electronic GmbH, Cologne, Germany) showed an increase in hydration and a decrease in sebum, pH and TEWL for both treatments. There were no statistically significant differences between the treatments. Combining chemical peeling of gluconolactone with oxybrasion and microneedle mesotherapy is a good method to seal the hydrolipid barrier and increase skin hydration.

Metabolomic differences between exanthematous drug eruption and infectious mononucleosis [PMID: 39387831 · 2024]
Liu Y, Guan Q, Liu L, et al. · Skin Res Technol (2024)

Exanthematous drug eruption and infectious mononucleosis (IM) are both exanthematous diseases. Current research on exanthematous drug eruption and IM mainly targets identifying these disorders, the resulting differences at the metabolism level have not yet been systematically analyzed. A total of 30 cases of exanthematous drug eruption and IM, 10 patients without exanthema and 10 healthy volunteers were enrolled, 3&#xa0;mL of fasting venous blood was collected, the serum metabolite content was detected by gas chromatography-mass spectrometry metabolomics. A total of 165 metabolites were identified, exhibiting significant differences in plasma metabolic trends between exanthematous drug eruption and IM, and pinpointed 28 potential biomarkers. Notable changes were seen in the metabolic activities of the pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA-cycle), and galactose metabolism, characterized by increased levels of gluconate, gluconolactone, glucose, galactaric acid, and mannose, along with decreased amounts of pyruvic acid, succinic acid, malic acid, and glycerol, indicating an impairment in the exanthematous drug eruption group's capacity to endure oxidative stress and regulate energy metabolism. In contrast to its medication without rash counterpart, the exanthematous drug eruption group's plasma displayed distinct metabolic routes, predominantly in the processing of arginine and proline, along with the TCA. This resulted in a marked reduction in urea levels and a rise in pyruvate, citrate, and ornithine, indicating hypoxic stress as the primary cause of these rashes. In contrast to the healthy control group, the IM group showed 26 potential biomarkers, marked by increased levels of ketoglutaric acid, malic acid, pyruvic acid, and oxoglutaric acid, and reduced amounts of glutamine, galacturonic acid, arachidonic acid, trimethylphosphonic acid ester, gluconolactone, and indole acetic acid. Mainly, the metabolic pathways included the TCA, breaking down alanine, aspartate and glutamate metabolism, and the processing of D-glutamine and D-glutamate metabolism, underscoring the body's crucial role in generating energy and inflammatory agents through the citric acid cycle. The comparison of serum metabolomic features of exanthematous drug eruptions and IM outlines a unique pattern closely related to the differences in the pathogenesis of these two exanthematous diseases.

Injectable bone cement based on magnesium potassium phosphate and cross-linked alginate hydrogel designed for minimally invasive orthopedic procedures [PMID: 39217204 · 2024]
Wekwejt M, Jesiołkiewicz R, Mielewczyk-Gryń A, et al. · Sci Rep (2024)

Bone cement based on magnesium phosphate has extremely favorable properties for its application as a bioactive bone substitute. However, further improvement is still expected due to difficult injectability and high brittleness. This paper reported the preparation of novel biocomposite cement, classified as dual-setting, obtained through ceramic hydration reaction and polymer cross-linking. Cement was composed of magnesium potassium phosphate and sodium alginate cross-linked with calcium carbonate and gluconolactone. The properties of the obtained composite material and the influence of sodium alginate modification on cement reaction were investigated. Our results indicated that proposed cements have several advantages compared to ceramic cement, like shortened curing time, diverse microstructure, increased wettability and biodegradability and improved paste cohesion and injectability. The magnesium phosphate cement with 1.50% sodium alginate obtained using a powder-to-liquid ratio of 2.5&#xa0;g/mL and cross-linking ratio 90/120 of GDL/CC showed the most favorable properties, with no adverse effect on mechanical strength and osteoblasts cytocompatibility. Overall, our research suggested that this novel cement might have promising medical application prospects, especially in minimally invasive procedures.

Formulation of Ascorbic Acid and Betaine-based Therapeutic Deep Eutectic System for Enhanced Transdermal Delivery of Ascorbic Acid [PMID: 38794349 · 2024]
Song JE, Jun SH, Ryoo JY, et al. · Pharmaceutics (2024)

L-ascorbic acid (AA), a potent antioxidant, is commonly used topically in the pharmaceutical and cosmetic fields. However, the incorporation of AA into topical formulations is difficult because of its highly unstable nature and relatively poor skin permeability. In this study, we propose an alternative strategy for improving the solubility and topical delivery of AA through its conversion to a therapeutic deep eutectic system (THEDES). AA and betaine (Bet)-based THEDESs were prepared at certain molar ratios and characterized using polarized optical microscopy, Fourier transform infrared spectroscopy, and differential scanning calorimetry. Solubility tests showed that AA in the form of THEDES was readily soluble in various polyols (glycerin, 1,3-butylene glycol, dipropylene glycol, and 1,3-propanediol) at a high concentration (approximately 40%). Furthermore, compared to AA alone or the physical mixture of AA and Bet, AA-based THEDES significantly enhanced AA delivery through porcine skin. In an in vivo human study, THEDES-containing serum reduced the markers of aging and induced an even skin tone. These findings indicate the utility of AA and Bet-based THEDES as novel transdermal delivery systems for AA. Furthermore, our approach also showed good extension to developing gluconolactone, a well-known natural antioxidant, and Bet-based THEDES, showing potential application in transdermal delivery systems.

Frequently Asked Questions (AEO Position 0)

Q1. What are the official 7-track regulatory label names for GLUCONOLACTONE?
Standard label names are US PCPC INCI: 'GLUCONOLACTONE', EU CosIng: 'GLUCONOLACTONE', KR MFDS: 'GLUCONOLACTONE (KR MFDS Registered)', CN NMPA IECIC: '葡糖酸内酯', and JP JCIA: 'GLUCONOLACTONE'.
Q2. Is GLUCONOLACTONE restricted or permitted in EU, US, KR, CN, and JP cosmetics?
Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
Q3. What is the typical formulation concentration and optimal pH window for GLUCONOLACTONE?
In aqueous_serum systems, GLUCONOLACTONE is typically formulated between 1% and 10% (median 4%), with an optimal stability window of pH 3.6–4.8.
Q4. What are the known formulation incompatibilities and synergy pairings for GLUCONOLACTONE?
Recommended synergy pairings include LACTOBIONIC ACID, SALICYLIC ACID, ARGININE, SODIUM CITRATE, POLYACRYLATE CROSSPOLYMER-6. Key incompatibilities to avoid: CRITICAL FORMULATION HAZARD (pH Drift): Slowly hydrolyzes in water from a neutral lactone ring into free Gluconic Acid (pKa 3.86) over days/weeks, causing severe pH drop (down to pH < 3.0) and emulsion/viscosity breakdown! Pre-equilibrate in warm water and buffer with Sodium Citrate / Arginine + use SEPIMAX ZEN.